Results 11 to 20 of about 4,829 (180)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases

open access: yesFrontiers in Oncology, 2021
Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj   +1 more source

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

open access: yesMetabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj   +1 more source

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

open access: yesCurrent Oncology, 2021
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh   +3 more
doaj   +1 more source

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment [PDF]

open access: yeseJHaem
Takafumi Tsushima   +12 more
doaj   +2 more sources

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

open access: yesMolecules, 2023
Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang   +3 more
doaj   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

open access: yesHaematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson   +14 more
doaj   +1 more source

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome

open access: yesFrontiers in Immunology, 2022
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang   +6 more
doaj   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase

open access: yesJournal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu   +3 more
doaj   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

open access: yesHaematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat   +7 more
doaj   +1 more source

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

open access: yesFrontiers in Immunology, 2021
Low-molecular weight chemical compounds have a longstanding history as drugs. Target specificity and binding efficiency represent major obstacles for small molecules to become clinically relevant. Protein kinases are attractive cellular targets; however,
Rula Zain, Rula Zain, Mauno Vihinen
doaj   +1 more source

Home - About - Disclaimer - Privacy